NASDAQ:DRUG Bright Minds Biosciences (DRUG) Stock Price, News & Analysis $42.17 -0.80 (-1.86%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$42.05 -0.12 (-0.28%) As of 09/9/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Bright Minds Biosciences Stock (NASDAQ:DRUG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get DRUG alerts:Sign Up Key Stats Today's Range$39.70▼$42.9950-Day Range$24.36▼$45.5552-Week Range$0.94▼$79.02Volume106,715 shsAverage Volume64,405 shsMarket Capitalization$296.88 millionP/E RatioN/ADividend YieldN/APrice Target$81.00Consensus RatingBuy Company Overview Bright Minds Biosciences Inc., trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments. The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders. Its second program, BMB-103, is in preclinical development targeting neuroinflammation and neuronal survival pathways relevant to Alzheimer’s disease. Bright Minds Biosciences operates research facilities in Vancouver and Montreal, collaborating with academic institutions and industry partners to advance its pipeline through both early-stage and later-stage clinical studies. Founded in 2020, Bright Minds completed its initial public listing to support ongoing research and development activities. The company’s leadership team includes experienced researchers, medicinal chemists and clinical development experts committed to translating cutting-edge neuroscience into scalable therapies. By focusing on small-molecule alternatives to traditional biologics, Bright Minds Biosciences seeks to offer patients oral treatments with favorable safety profiles and broad commercial applicability.AI Generated. May Contain Errors. Read More Bright Minds Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreDRUG MarketRank™: Bright Minds Biosciences scored higher than 63% of companies evaluated by MarketBeat, and ranked 440th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingBuy Consensus RatingBright Minds Biosciences has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Upside PotentialBright Minds Biosciences has a consensus price target of $81.00, representing about 92.1% upside from its current price of $42.17.Amount of Analyst CoverageBright Minds Biosciences has only been the subject of 3 research reports in the past 90 days.Read more about Bright Minds Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Bright Minds Biosciences are expected to decrease in the coming year, from ($1.24) to ($3.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bright Minds Biosciences is -45.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bright Minds Biosciences is -45.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBright Minds Biosciences has a P/B Ratio of 45.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.09% of the float of Bright Minds Biosciences has been sold short.Short Interest Ratio / Days to CoverBright Minds Biosciences has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Bright Minds Biosciences has recently decreased by 1.13%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBright Minds Biosciences does not currently pay a dividend.Dividend GrowthBright Minds Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.09% of the float of Bright Minds Biosciences has been sold short.Short Interest Ratio / Days to CoverBright Minds Biosciences has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Bright Minds Biosciences has recently decreased by 1.13%, indicating that investor sentiment is improving. News and Social Media3.3 / 5News Sentiment0.88 News SentimentBright Minds Biosciences has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Bright Minds Biosciences this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added Bright Minds Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bright Minds Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders42.66% of the stock of Bright Minds Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.52% of the stock of Bright Minds Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bright Minds Biosciences' insider trading history. Receive DRUG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bright Minds Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DRUG Stock News HeadlinesBTIG Research Initiates Coverage on Bright Minds Biosciences (NASDAQ:DRUG)September 9 at 2:50 AM | americanbankingnews.comBTIG Initiates Coverage of Bright Minds Biosciences (DRUG) with Buy RecommendationSeptember 8 at 3:12 PM | msn.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks. | American Alternative (Ad)Large Patient Population Is Key Driver For Bright Minds' GrowthSeptember 8 at 3:12 PM | finance.yahoo.comBright Minds announces ATM offering up to $100 millionSeptember 5, 2025 | msn.comBright Minds Biosciences Launches $100 Million At-The-Market OfferingSeptember 5, 2025 | msn.comBRIGHT MINDS BIOSCIENCES ANNOUNCES AT-THE-MARKET OFFERINGSeptember 4, 2025 | finance.yahoo.comPsychedelic: Bright Minds reports preclinical BMB-201 resultsSeptember 4, 2025 | msn.comSee More Headlines DRUG Stock Analysis - Frequently Asked Questions How have DRUG shares performed this year? Bright Minds Biosciences' stock was trading at $36.02 at the beginning of the year. Since then, DRUG shares have increased by 17.1% and is now trading at $42.17. How were Bright Minds Biosciences' earnings last quarter? Bright Minds Biosciences Inc. (NASDAQ:DRUG) released its earnings results on Thursday, August, 14th. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.06. When did Bright Minds Biosciences' stock split? Bright Minds Biosciences's stock reverse split on Friday, July 14th 2023.The 1-5 reverse split was announced on Friday, July 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. Who are Bright Minds Biosciences' major shareholders? Bright Minds Biosciences' top institutional investors include Sio Capital Management LLC (7.28%), Perceptive Advisors LLC (5.98%), Geode Capital Management LLC (0.82%) and Walleye Capital LLC (0.76%). View institutional ownership trends. How do I buy shares of Bright Minds Biosciences? Shares of DRUG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bright Minds Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bright Minds Biosciences investors own include HubSpot (HUBS), Blink Charging (BLNK), ConocoPhillips (COP), Netflix (NFLX), ForgeRock (FORG) and SoFi Technologies (SOFI). Company Calendar Last Earnings8/14/2025Today9/09/2025Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DRUG CIK1827401 Webbrightmindsbio.com Phone64-7407-2515FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Bright Minds Biosciences$81.00 High Price Target$93.00 Low Price Target$72.00 Potential Upside/Downside+92.1%Consensus RatingBuy Rating Score (0-4)3.11 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($0.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.06 million Net MarginsN/A Pretax MarginN/A Return on Equity-20.96% Return on Assets-20.66% Debt Debt-to-Equity RatioN/A Current Ratio86.64 Quick Ratio86.64 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.92 per share Price / Book45.84Miscellaneous Outstanding Shares7,040,000Free Float4,039,000Market Cap$296.88 million OptionableNot Optionable Beta-6.13 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:DRUG) was last updated on 9/10/2025 by MarketBeat.com Staff From Our Partners“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredUnlock Friday's Full Potential: Two Simple Sentences that put profits in investors’ pocketsMost traders stick to the same routine each week. But a little-known market strategy has quietly delivered a 9...Eagle Publishing | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredPOP QUIZ: What’s the #1 indicator of a stock’s success? (Nope, not earnings or sales)What indicator do you think is the #1 predictor of stock market success? Most would guess earnings or sales...The Oxford Club | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bright Minds Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bright Minds Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.